“…There are many drugs on the market containing an adamantyl ring as a key structural subunit used for treatment of serious diseases such as Parkinson's (amantadine) ( Crosby et al, 2003 ), Alzheimer's (memantine) ( Reisberg et al, 2003 ), type2 diabetes (saxaglipitin, vildagliptin) ( Ahren, 2009 ), influenza (rimantidine) ( Jefferson et al, 2004 ), skin disorders (adapalene) ( Thiboutot et al, 2005 ), among others. ( Wanka et al, 2013 ) These types of compounds target a variety of receptors and enzymes of therapeutic interest, including cannabinoid receptors (CB1, CB2) ( Lu et al, 2005 ; Dixon et al, 2010 ), NMDA receptors ( Gilling et al, 2009 ), ion channels ( Stouffer et al, 2008 ), epoxide hydrolase ( Burmistrov et al, 2018 ), 11β-hydroxy steroid dehydrogenase type I ( Ye et al, 2017 ), cholinesterases ( Kwong et al, 2017 ), and tyrosine kinases ( Kaur et al, 2005 ). In many of these cases, especially for cannabinoid receptors, incorporation of the adamantane moiety improves the compound’s binding properties through favorable hydrophobic interactions with key residues within the binding pocket.…”